Early Detection
of Cardiac Amyloidosis
The patented* SYGNAL algorithm analyzes standard 12-lead ECGs using weighted analysis of ECG-derived parameters — non-invasive, cloud-based, results in under one minute.
* patent pending
The Most Underestimated Life-Limiting Heart Disease
Cardiac amyloidosis is one of the most frequently overlooked heart diseases — with grave consequences for patients who go undiagnosed.
Frequently Misdiagnosed
Approximately one-third of patients receive an incorrect initial diagnosis. Cardiac amyloidosis masquerades as HFpEF — causing years of inadequate treatment.
Devastating Diagnostic Delay
The average time from first symptoms to correct diagnosis is 6.1 years for ATTRwt and 5.7 years for hereditary ATTRv — years of irreversible cardiac damage.
Life-Threatening Condition
5-year mortality of cardiac amyloidosis is approximately 60%. AL amyloidosis with cardiac involvement carries up to 50% mortality per year after first decompensation.
Vastly Underestimated Prevalence
25% of patients over 80 show transthyretin deposits in the heart. 13% of HFpEF patients over 60 are affected — the vast majority remain undiagnosed.
Data source: Literature analysis of 23 studies on ATTR cardiomyopathy. These diagnostic delays represent years of disease progression and missed treatment opportunities.
Discover SYGNALOnly 10% of Patients Are Diagnosed
Cardiac amyloidosis affects an estimated 3 million people worldwide — yet the vast majority go undetected. The reason: a missing screening infrastructure.
No Screening Available
No cardiac amyloidosis screening available — existing tools lack sensitivity & specificity
Lack of Availability
Current diagnostic tools lack ease-of-use and broad availability
High Therapy Costs
Therapies now exist — but cost approx. €300,000 p.a. per patient, demanding precise diagnosis first
SYGNAL "Flip the Ratio"
Through systematic ECG screening, we reverse the ratio — from a diagnostic vacuum to widespread early detection.
2.7M patients undiagnosed — only 300K detected, only 30K treated
2.7M patients diagnosed — and over 2.7M effectively treated
Closing the Diagnostic Gap
Cardiac amyloidosis is one of the most frequently overlooked heart diseases — with an average diagnostic delay of over 5 years and a 5-year mortality of approximately 60%.
At MYCOR, we have made it our mission to close this gap. With the SYGNAL algorithm, we are developing an algorithm-based screening solution that enables early detection of cardiac amyloidosis — non-invasively, cost-effectively, and in under one minute.
Our interdisciplinary team combines clinical expertise from leading university hospitals with state-of-the-art AI technology — to give patients timely diagnoses and access to life-saving therapies.
Patient Focus
The goal is early confirmation of diagnosis to initiate timely, effective therapy — improving both quality of life and prognosis. The earlier the diagnosis is made, the better the chances of achieving these therapeutic goals.
Scientific Evidence
Our work is built on rigorous scientific methodology and clinical validation. We pursue the highest quality and evidence standards.
Innovation
We harness cutting-edge technology to solve complex medical challenges and sustainably improve healthcare.
The patented* SYGNAL Algorithm
SYGNAL uses data from a standard 12-lead ECG device and analyzes it with a transparent, deterministic algorithm — no black box — to detect signs of cardiac amyloidosis. Non-invasive, affordable, results in under one minute.
* patent pending
Non-Invasive
Analyzes the standard 12-lead ECG you already record — no biopsy, no additional procedures, no extra patient burden.
>85% Sensitivity*
Reliably identifies patients with cardiac amyloidosis, minimizing missed diagnoses that lead to delayed care.
89% Specificity*
A low false-positive rate that protects your workflow from unnecessary downstream workup and keeps physicians confident.
Cloud-Based
Seamlessly integrates into existing hospital IT infrastructure — no dedicated hardware, no complex installation.
Result in Under 1 Minute
Instant algorithmic analysis delivers a clear, actionable screening result at the point of care.
Numbers That Matter
Performance metrics from internal validation studies. Clinical data on file. Results may vary depending on population and ECG quality.
*if supported by us
How SYGNAL Works
Three steps. No new hardware. No disruption to your clinical workflow.
Record with Standard ECG Device*
Use your existing 12-lead ECG device. No new equipment, no workflow changes. The patient experience remains exactly the same.
SYGNAL Cloud Analysis
The ECG data is securely transmitted to our cloud platform, where the SYGNAL algorithm performs weighted analysis of ECG-derived parameters in real time.
Result in Under 1 Minute
A clear, actionable screening report is delivered directly to your clinical system — enabling immediate, informed decision-making.
*if supported by us
Demonstrated Expertise
Leading cardiologists, AI engineers, and entrepreneurs united by a shared mission — to make cardiac amyloidosis detectable before it's too late.
Dr. med. Christian Fach
Managing Director of MyCor GmbH | Co-Founder
Specialist in internal medicine and cardiology, and head of Kardiologie Schadowstraße – Düsseldorfer Herz. Proven expertise in developing innovative outpatient care structures and cross-sector medical care.
Prof. Dr. med. Reza Wakili
Co-Founder
Deputy Director of Cardiology at University Hospital Frankfurt. Expert in electrophysiology and cardiac arrhythmia.
Dipl.-Inf. Jan Knobeloch
CTO & Co-Founder
Diplom-Informatiker (Computer Science), AI architect, and co-founding mind behind SYGNAL. Translates technological vision into scalable AI products and leads the development of the SYGNAL algorithm with a focus on machine learning, pattern recognition, and AI-based diagnostics.
Dipl.-Oec. Markus Ott
COO & Co-Founder
Diplom-Economist, serial entrepreneur, and startup founder focused on company building, business development, and strategic partnerships. Proven ability to develop, scale, and operationally manage new business models.
Affiliated Institutions
Understanding Amyloidosis
In-depth knowledge about one of the most challenging disease groups in modern medicine — from pathophysiology to the emerging therapeutic revolution.
Everything About SYGNAL & Amyloidosis
Answers to the most important questions about cardiac amyloidosis, the SYGNAL algorithm, clinical integration, and treatment options.
More questions? Contact us:
Ready for the Next Generation
of Cardiac Diagnostics?
Partner with MYCOR to bring algorithm-based cardiac amyloidosis screening to your institution. Contact us for a demo, collaboration inquiries, or investment opportunities.